← Back to Search

Ketone Ester

12.5 g/d of C6 ketone di-ester for Pharmacokinetics

N/A
Waitlist Available
Led By Dawn Beckman, MD
Research Sponsored by BHB Therapeutics, Ireland LTD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0-8 hours
Awards & highlights

Study Summary

Randomized, parallel repeat dose pharmacokinetic study of C6 ketone di-ester in a ready to drink beverage matrix.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0-8 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0-8 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the curve (AUC)
Cmax
Elimination half-life
+1 more

Trial Design

3Treatment groups
Active Control
Group I: 12.5 g/d of C6 ketone di-esterActive Control1 Intervention
Low dose of ketone di-ester.
Group II: 25 g/d of C6 ketone di-esterActive Control1 Intervention
Middle dose of ketone di-ester.
Group III: 50 g/d of C6 ketone di-esterActive Control1 Intervention
Highest dose of ketone di-ester.

Find a Location

Who is running the clinical trial?

BHB Therapeutics, Ireland LTDLead Sponsor
2 Previous Clinical Trials
102 Total Patients Enrolled
1 Trials studying Pharmacokinetics
12 Patients Enrolled for Pharmacokinetics
Mérieux NutriSciences BiofortisUNKNOWN
1 Previous Clinical Trials
12 Total Patients Enrolled
1 Trials studying Pharmacokinetics
12 Patients Enrolled for Pharmacokinetics
Dawn Beckman, MDPrincipal InvestigatorMérieux NutriSciences Biofortis
8 Previous Clinical Trials
451 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~11 spots leftby Apr 2025